Becton, Dickinson and Company (NYSE:BDX – Get Free Report) and Daxor (NASDAQ:DXR – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Risk and Volatility
Becton, Dickinson and Company has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Becton, Dickinson and Company and Daxor, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Becton, Dickinson and Company | 0 | 0 | 6 | 0 | 3.00 |
| Daxor | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares Becton, Dickinson and Company and Daxor’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Becton, Dickinson and Company | 8.55% | 14.89% | 6.98% |
| Daxor | N/A | N/A | N/A |
Valuation & Earnings
This table compares Becton, Dickinson and Company and Daxor”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Becton, Dickinson and Company | $20.18 billion | 3.45 | $1.71 billion | $5.94 | 40.44 |
| Daxor | N/A | N/A | N/A | N/A | N/A |
Becton, Dickinson and Company has higher revenue and earnings than Daxor.
Insider and Institutional Ownership
87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 59.0% of Daxor shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Becton, Dickinson and Company beats Daxor on 7 of the 9 factors compared between the two stocks.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
